Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Official Title

Liquid Biopsy Evaluation and Repository Development at Princess Margaret


The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumour specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumour progression and response to treatment at multiple time points during a patient's course of disease.

Trial Description

Primary Outcome:

  • Collection and annotation of biospecimens
Secondary Outcome:
  • Electronic Consenting
  • Correlative Studies Questionnaire

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society